Loading…
CEFTAZIDIME FOR is a brand name for Ceftazidime, supplied as a powder for solution. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Ceftazidime for Injection BP (Ceftazidime pentahydrate) is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections Pneumonia caused by Pseudomonas aeruginosa; Haemophilus influenzae including…
Verbatim from this product's HC label. Tap a section to expand.
2 Clinical Trial Adverse Reactions 05/2023 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES .............................................................................................
2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................................
4 1 INDICATIONS .................................................................................................................. 1 Pediatrics .................................................................................................................
2 Geriatrics ................................................................................................................. 5 2 CONTRAINDICATIONS .....................................................................................................
5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ................................................................ 6 4 DOSAGE AND ADMINISTRATION .................................................................................... 1 Dosing Considerations .............................................................................................
2 Recommended Dose and Dosage Adjustment ........................................................ 3 Reconstitution ......................................................................................................... 4 Administration .......................................................................................................
12 5 OVERDOSAGE ............................................................................................................... 13
2 Clinical Trial Adverse Reactions 05/2023 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES .............................................................................................
2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................................
4 1 INDICATIONS .................................................................................................................. 1 Pediatrics .................................................................................................................
2 Geriatrics ................................................................................................................. 5 2 CONTRAINDICATIONS .....................................................................................................
5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ................................................................ 6 4 DOSAGE AND ADMINISTRATION .................................................................................... 1 Dosing Considerations .............................................................................................
2 Recommended Dose and Dosage Adjustment ........................................................ 3 Reconstitution ......................................................................................................... 4 Administration .......................................................................................................
12 5 OVERDOSAGE ............................................................................................................... 13 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING .................................. 14 7 WARNINGS AND PRECAUTIONS ....................................................................................
, Clostridium difficile-Associated Disease, Immune, Neurologic, Renal, Skin 05/2023
Ceftazidime for Injection BP is contraindicated for patients who have shown hypersensitivity to ceftazidime or the cephalosporin group of antibiotics. See 7 WARNINGS AND PRECAUTIONS and 9 DRUG INTERACTIONS. Ceftazidime for Injection BP Page 6 of 60
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
1 Special Populations................................................................................................ 1 Pregnant Women ............................................................................................... 2 Breast-feeding ...................................................................................................
3 Pediatrics ........................................................................................................... 4 Geriatrics ...........................................................................................................
19 8 ADVERSE REACTIONS .................................................................................................... 1 Adverse Reaction Overview ...................................................................................
2 Clinical Trial Adverse Reactions ............................................................................. 3 Less Common Clinical Trial Adverse Reactions ...................................................... 4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data ............................................................................................................
5 Post-Market Adverse Reactions ............................................................................ 20 9 DRUG INTERACTIONS ................................................................................................... 2 Drug Interactions Overview ...................................................................................
4 Drug-Drug Interactions .......................................................................................... 5 Drug-Food Interactions.......................................................................................... 6 Drug-Herb Interactions ..........................................................................................
7 Drug-Laboratory Test Interactions......................................................................... 22 10 CLINICAL PHARMACOLOGY ........................................................................................... 1 Mechanism of Action.............................................................................................
2 Pharmacodynamics ............................................................................................... 3 Pharmacokinetics ..................................................................................................
23 11 STORAGE, STABILITY AND DISPOSAL............................................................................. 35 12 SPECIAL HANDLING INSTRUCTIONS .............................................................................. 35 PART II: SCIENTIFIC INFORMATION ........................................................................................
36 13 PHARMACEUTICAL INFORMATION ............................................................................... 36 14 CLINICAL TRIALS ...........................................................................................................
36 15 MICROBIOLOGY ............................................................................................................ 37 16 NON-CLINICAL TOXICOLOGY .........................................................................................
42 17 SUPPORTING PRODUCT MONOGRAPHS ....................................................................... 53 PATIENT MEDICATION INFORMATION ................................................................................... 54 Ceftazidime for Injection BP Page 4 of 60 PART I: HEALTH PROFESSIONAL INFORMATION 1 INDICATIONS Ceftazidime for Injection BP (Ceftazidime pentahydrate) is indicated for the treatment of patients […]